YONDELIS

This brand name is authorized in United States. It is also authorized in Austria, Canada, Croatia, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Mexico, Netherlands, Poland, Romania, Singapore, South Africa, Spain, Turkey, UK.

Active ingredients

The drug YONDELIS contains one active pharmaceutical ingredient (API):

1	Trabectedin UNII ID0YZQ2TCP - TRABECTEDIN
	Trabectedin binds to the minor groove of deoxyribonucleic acid (DNA), bending the helix to the major groove. This binding to DNA triggers a cascade of events affecting several transcription factors, DNA binding proteins, and DNA repair pathways, resulting in perturbation of the cell cycle. Trabectedin has been shown to exert antiproliferative in vitro and in vivo activity against a range of human tumour cell lines and experimental tumours, including malignancies such as sarcoma, breast, non-small cell lung, ovarian and melanoma.
	Read more about Trabectedin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
YONDELIS Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01CX01	Trabectedin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01C Plant alkaloids and other natural products → L01CX Other plant alkaloids and natural products
Discover more medicines within L01CX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02351528
EE	Ravimiamet	1327317, 1327328, 1847796
ES	Centro de información online de medicamentos de la AEMPS	07417001, 07417002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	015532, 015598
FR	Base de données publique des médicaments	60457338, 66602114
GB	Medicines & Healthcare Products Regulatory Agency	155482, 155485
HK	Department of Health Drug Office	59078
IL	מִשְׂרַד הַבְּרִיאוּת	6626
IT	Agenzia del Farmaco	038165015, 038165027
JP	医薬品医療機器総合機構	4291431D1027, 4291431D2023
LT	Valstybinė vaistų kontrolės tarnyba	1029593, 1029594
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	220M2009
NL	Z-Index G-Standaard, PRK	107654, 107662
PL	Rejestru Produktów Leczniczych	100189891, 100313397
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W52365001, W52366001
SG	Health Sciences Authority	13661P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699650772737
US	FDA, National Drug Code	59676-610
ZA	Health Products Regulatory Authority	43/26/0557